<DOC>
	<DOCNO>NCT01650259</DOCNO>
	<brief_summary>Study investigate safety efficacy long-term daily use Trazenta® Tablets monotherapy patient type 2 diabetes mellitus assess baseline characteristic patient type 2 diabetes mellitus start Trazenta® Tablets oral antidiabetic monotherapy ( naïve switch prior therapy different oral antidiabetic drug ) .</brief_summary>
	<brief_title>Long-term Daily Use Trazenta® Tablets Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Male female patient type 2 Diabetes Mellitus never treat Trazenta tablet / Linagliptin ( monotherapy ) enrollment . ( Trazenta group ) Patients type 2 Diabetes Mellitus start oral antidiabetic monotherapy ( naïve switch prior therapy different oral antidiabetic drug ( OAD ) ) except Trazenta tablet . ( OAD group ) Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>